{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:57Z","timestamp":1789512897296,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00774-020-01180-4","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T14:02:38Z","timestamp":1609596158000},"page":"463-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-9414","authenticated-orcid":false,"given":"Sakae","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoka","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-3981","authenticated-orcid":false,"given":"Naoki","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal Osteoporos N Engl J Med 374:254\u2013262","journal-title":"Postmenopausal Osteoporos N Engl J Med"},{"key":"1180_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276\u20131287","journal-title":"Lancet"},{"key":"1180_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"1180_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00003086-199803000-00007","volume":"348","author":"S Kitamura","year":"1998","unstructured":"Kitamura S, Hasegawa Y, Suzuki S, Sasaki R, Iwata H, Wingstrand H, Thorngren KG (1998) Functional outcome after hip fracture in Japan. Clin Orthop Relat Res 348:29\u201336","journal-title":"Clin Orthop Relat Res"},{"key":"1180_CR6","first-page":"797","volume":"22","author":"M Iki","year":"2012","unstructured":"Iki M (2012) Epidemiology of osteoporosis in Japan (in Japanese). Clin Calcium 22:797\u2013803","journal-title":"Clin Calcium"},{"key":"1180_CR7","unstructured":"International Osteoporosis Foundation (2009) The Asian Audit: epidemiology, costs and burden of osteoporosis in Asia 2009. https:\/\/www.iofbonehealth.org\/sites\/default\/files\/PDFs\/Audit%20Asia\/Asian_regional_audit_2009.pdf. Accessed 3 Feb 2020"},{"key":"1180_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401\u2013419","journal-title":"Nat Rev Drug Discov"},{"key":"1180_CR9","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059\u20131066","journal-title":"J Bone Miner Res"},{"key":"1180_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11914-006-0012-7","volume":"4","author":"MR McClung","year":"2006","unstructured":"McClung MR (2006) Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4:28\u201333","journal-title":"Curr Osteoporos Rep"},{"key":"1180_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1180_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599\u20132607","journal-title":"J Clin Endocrinol Metab"},{"key":"1180_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1180_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","volume":"26","author":"T Sugimoto","year":"2015","unstructured":"Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I et al (2015) Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int 26:765\u2013774","journal-title":"Osteoporos Int"},{"key":"1180_CR15","first-page":"453","volume":"39","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Mizutani H, Tsuruya E, Mochikuzi Y, Kuge K, Okubo N (2018) Safety and efficacy of long-term denosumab treatment in Japanese patients with osteoporosis in daily clinical practice: an interim analysis of a post-marketing surveillance study. Ther Res 39:453\u2013465","journal-title":"Ther Res"},{"key":"1180_CR16","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"1180_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404\u2013413","journal-title":"Biometrika"},{"key":"1180_CR18","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1513\/AnnalsATS.201308-276RM","volume":"11","author":"D Price","year":"2014","unstructured":"Price D, Bateman ED, Chisholm A, Papadopoulos NG, Bosnic-Anticevich S, Pizzichini E, Hillyer EV, Buist AS (2014) Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann Am Thorac Soc 11:S92\u2013S98","journal-title":"Ann Am Thorac Soc"},{"key":"1180_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.536","volume":"27","author":"MR McClung","year":"2012","unstructured":"McClung MR, Boonen S, Torring O, Roux C, Rizzoli R, Bone HG, Benhamou CL, Lems WF, Minisola S, Halse J, Hoeck HC, Eastell R, Wang A, Siddhanti S, Cummings SR (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211\u2013218","journal-title":"J Bone Miner Res"},{"key":"1180_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.joca.2015.07.017","volume":"24","author":"T Iidaka","year":"2016","unstructured":"Iidaka T, Muraki S, Akune T, Oka H, Kodama R, Tanaka S, Kawaguchi H, Nakamura K, Yoshimura N (2016) Prevalence of radiographic hip osteoarthritis and its association with hip pain in Japanese men and women: the ROAD study. Osteoarthr Cartil 24:117\u2013123","journal-title":"Osteoarthr Cartil"},{"key":"1180_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00774-007-0768-6","volume":"25","author":"M Kamatari","year":"2007","unstructured":"Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302\u2013309","journal-title":"J Bone Miner Metab"},{"key":"1180_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0278-2391(09)00013-5","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J Oral Maxillofac Surg 67:2\u201312","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01180-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T04:40:14Z","timestamp":1619671214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01180-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01180-4","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S. Tanaka received consulting fees, speaking fees and\/or honoraria from Daiichi Sankyo Co., Ltd. H. Mizutani, E. Tsuruya, R. Fukuda, K. Kuge and N. Okubo are employees of Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Japanese GPSP guidelines. Under these guidelines, the requirement for written informed consent is waived because treatment is in accordance with clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}